[go: up one dir, main page]

US20020106791A1 - Beta taipoxin as a cell growth factor and method - Google Patents

Beta taipoxin as a cell growth factor and method Download PDF

Info

Publication number
US20020106791A1
US20020106791A1 US10/004,085 US408501A US2002106791A1 US 20020106791 A1 US20020106791 A1 US 20020106791A1 US 408501 A US408501 A US 408501A US 2002106791 A1 US2002106791 A1 US 2002106791A1
Authority
US
United States
Prior art keywords
cell growth
growth factor
culture medium
taipoxin
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/004,085
Inventor
Binie Lipps
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/004,085 priority Critical patent/US20020106791A1/en
Publication of US20020106791A1 publication Critical patent/US20020106791A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/0037Serum-free medium, which may still contain naturally-sourced components
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998Proteins not provided for elsewhere

Definitions

  • the present invention relates to the discovery of non-toxic beta taipoxin as a cell growth factor and a potent mitogen from poisonous snake venom.
  • Said composition consists of a polypeptide of beta taipoxin having molecular weight approximately 14,000 daltons and is free of toxic effects.
  • Taipoxin as a whole intact molecule isolated from the venom of the Australian taipan Oxyuranus s. scutellatus is the most lethal neurotoxin.
  • the whole molecule of taipoxin is a complex, composed of three subunits designated as alpha, beta and gamma, having molecular weight 45,6000 daltons.
  • Taipoxin can not be isolated by ion-xchange chromatography, since ion exchangers tend to dissociate the active toxin complex.
  • the major lethality of taipoxin is due to the very basic alpha subunit.
  • the molecular weights of alpha, beta and gamma subunits of taipoxin are 13,750, 13,473 and 18,354 daltons respectively.
  • EGF epidermal growth factor
  • FGF fibroblast growth factor
  • OGF nerve growth factor
  • PDGF platelet derived growth factor
  • the beta taipoxin as a cell growth factor can be used to grow cells in serum free medium. Routinely, cells are grown in the presence of 5 to 20% fetal bovine serum (FBS) for research or production. The purification of products derived from cells grown in serum containing medium is a cumbersome task and furthermore, fetal bovine serum is the most expensive ingredient of the medium A mitogen like cell growth factor will provide serum free environment with adequate cell proliferation.
  • FBS fetal bovine serum
  • a further object of this invention is to provide non-toxic beta taipoxin having mitogenic activity as a composition for the promotion of rapid burn and wound healing. In the case of cuts, surgical incisions, and abrasions to lessen the risk of infection and to shorten recovery time.
  • Cell growth factor has been isolated as the beta subunit of taipoxin by fractionating Oxyuranus s. scutellatus snake venom by high pressure liquid chromatography. After testing for mitogenic activity in all fractions, the mitogenic activity was revealed in one of the fractions.
  • Cell growth factor is a beta taipoxin; which is a non-toxic fraction of snake venom and is a potent mitogen.
  • Cell growth factor has been isolated from the venom of the poisonous snake species Oxyuranus s. scutellatus.
  • the concentration of 0.1 ⁇ g/ml of the beta taipoxin non-toxic subunit becomes a cell growth factor and in serum free medium it gives growth equivalent to medium containing 10% serum for a wide range of cells.
  • Cell growth factor is a beta taipoxin peptide having a molecular weight 14,000 daltons.
  • beta taipoxin as a cell growth factor acts as a potent mitogen.
  • the cut portion of mouse hip skin healed much faster when cell growth factor was applied as compared to the control counter part.
  • Cell growth factor helped heal a chronic foot wound of a friend.
  • Cell growth factor is claimed as wound healer and its use may be extended to treat burns.
  • FIG. 1 is a high pressure liquid chromatography profile of Oxyuranus s. scutellatus venom, resolved into 11 major fractions. Peak number 6 is representative of beta taipoxin.
  • FIG. 2 is a high pressure liquid chromatography profile of concentrated fraction number 6 containing beta taipoxin.
  • FIG. 3 is an electrophoresis profile of beta taipoxin on a 14% Novex gel, showing the molecular weight in the vicinity of 14,000 daltons, when compared with Novex protein markers lysozyme, and trypsin inhibitor, having molecular weights 14,400 and 21,500 daltons respectively on 14 % precast gel.
  • Lanes 1 and 2 contain the cell growth factor, lane 3 contains the markers.
  • the cell growth factor consists essentially of a peptide of which first 15 amino acid sequence is: Asp-Leu-Val-Glu-Phe-Gly-Lys-Met-Ile-Glu-Cys-Ala-Ile-Arg-Asn, which is exactly similar to beta taipoxin. For convenience this sequence is referred herein as SEQ ID No: 1. It is believed that any peptide having the partial amino acid sequence SEQ ID No: 1 exhibits substantial utility as a cell growth promoter, a potent mitogen, regardless whether it is synthesized or derived from natural sources.
  • cell growth factor we mean a substance whose presence produces a substantial nmitogenic effect on various types of cells, and that the mitogenic effect is indicated, by an increase in cell growth or by a decreased duplication time of various types of cells.
  • the peptide cell growth factor contains the first fifteen amino acids at N-terminal as given by SEQ ID No: 1, and has a molecular weight of about 14,000 daltons revealed by electrophoresis which is similar to beta taipoxin.
  • cell growth factor is water soluble and stable at 4 ° C. storage for its biological activity.
  • Cell growth factor is stable at room temperature, 74 ° C. for several weeks and its biological mitogenic activity is not altered by exposing it to ultra violet light overnight.
  • Cell growth factor beta taipoxin
  • Cell growth factor may be obtained essentially as a fraction of venom, from species of poisonous snake.
  • Cell growth factor is preferably obtained from the venom of a species of Australian taipan snake, particularly the species Oxyuranus s. scutellatus.
  • the active cell growth factor a non-toxic beta taipoxin is preferably separated from fresh frozen venom, although lyophilized whole venom may also be used.
  • the liquid venom is diluted 1:1 with 0,01 M phosphate buffer saline (PBS) and preferably centrifuged to sediment insoluble debris, which can also be removed by filtration.
  • PBS phosphate buffer saline
  • the diluted and centrifuged 50 mg venom is loaded on high pressure liquid chromatography, from Toso Co. Japan and the ion exchange column from Polymer Laboratories UK, maintained at 20 ° C. temperature.
  • a plurality of fractions according to the relative ionic charge are eluted preferably, using gradient Tnzma(2-amino-2-(hydroxymethyl)propane-1,3-diol)-HCl buffer pH 7.3.
  • the Toso high pressure liquid chromatography automatically mixes 1.0 molar Triztna-HCL buffer with water to yield gradient Trizma-HCl buffer from 0.01 molar to 1.0 molar. Any suitable gradient buffer may be used and Trizma-HCl buffer having pH 6.0 to 8.0 can be used.
  • Fraction 6 represents the active cell growth factor of beta taipoxin.
  • the fraction containing the mitogenic active peptide may be used in this form as a cell growth promoter, but may also be and preferably is further purified to obtain 100% purity to substantially remove mitogenic inactive substances as well.
  • the mitogenic active fraction 6 is concentrated and dialyzed simultaneously using dialysis apparatus from Spectrum Co., to 1/20 volume and further purified by high pressure liquid chromatography as second run under identical conditions, such as gradient buffer temperature etc.
  • the second time running of the concentrate of the cell growth factor fraction 6 resolved into one peak (Drawing No. 2). This peak material is sequenced for its first fifteen amino acids from the N-terminal SEQ ID No:
  • each fraction was tested for the cell proliferative activity on rat adrenal pheochromocytoma, PC12, cells in concentrations ranging from 5 ⁇ g/ml to 0.1 ⁇ g/ml.
  • PC12 cells were maintained in Dulbecco Modified Eagle's Medium (DMEM) serum free medium and various concentrations of 11 fractions were added.
  • DMEM Dulbecco Modified Eagle's Medium
  • the growth pattern of PC12 cells in presence of each fraction was compared to the cells maintained in DMEM containing 10% serum. All fractions showed toxic effect when the concentration of the fraction was greater than 1 ⁇ g/ml.
  • fraction 6 of Oxyuranus S. scutellatus venom showed proliferative growth of PC12 cells at 1, 0.5 and 0.1 ⁇ g/ml concentration.
  • cell growth factor can be a wound healer.
  • Cell growth factor is stable at 4° C. for a long period of time.
  • Cell growth factor is non-toxic, when 50 ⁇ g in 0.5 ml is injected intraperitoneally in a 20 gram mouse. Being a cell growth promoter having a neurotrophic activity, this cell growth factor will be an excellent wound and burn healer.
  • the cell growth factor is beta taipoxin of the present invention is a particularly effective mitogenic agent. Since it is substantially free of toxic activity, the cell growth factor can be used to grow wide range of cells in the serum free medium. Further, it may be used for a rapid proliferation of cells either for research or for production purposes, also in the case of dermal monolayers to grow in vitro for the treatment of bum victims and for wound healing.
  • cell growth factor which is a beta taipoxin
  • its method of preparation of the present invention has utility for treating bums and wounds including chronic wounds.
  • the healing effects is accomplished by treating the wounds or cuts with cell growth factor having 100 ⁇ g/ml protein concentration in PBS in liquid form. It can be used after mixing with silvadene or any other appropriate ointment.
  • no scar is produced because the hard dead tissue on the wound sloughs off as a effect of cell growth factor.
  • the concentrated fraction number 6 which was obtained by initial fractionating the crude venom, resolved into a single peak on second time fractionation on high pressure liquid chromatography under identical conditions.
  • the peak material was estimated to have a molecular weight in the vicinity of 14,000 daltons, when compared with Novex protein markers lysozyme, and trypsin inhibitor, having molecular weights 14,400 and 21,500 daltons respectively on 14% precast gel (Drawing No. 3).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A peptide containing a sequence for the first fifteen amino acids from the N-terminal of Asn-Leu-Val-Glu-Phe-Gly-Lys-Met-Ile-Glu-Cys-Ala-Ile-Arg-Asn is used in a cell culture medium to promote cell growth in vitro and in the treatment of wounds. A method of preparation of the peptide is also claimed.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a division of application Ser. No. 08/237,129, filed May 3, 1994, now the disclosure of which is incorporated by reference, and a division of application Ser. No. 08/657,164, filed Jun. 3, 1996, now , the disclosure of which is incorporated by reference..[0001]
  • BACKGROUND OF THE INVENTION
  • The present invention relates to the discovery of non-toxic beta taipoxin as a cell growth factor and a potent mitogen from poisonous snake venom. Said composition consists of a polypeptide of beta taipoxin having molecular weight approximately 14,000 daltons and is free of toxic effects. [0002]
  • Taipoxin as a whole intact molecule isolated from the venom of the Australian taipan [0003] Oxyuranus s. scutellatus is the most lethal neurotoxin. The whole molecule of taipoxin is a complex, composed of three subunits designated as alpha, beta and gamma, having molecular weight 45,6000 daltons.
  • Taipoxin can not be isolated by ion-xchange chromatography, since ion exchangers tend to dissociate the active toxin complex. The major lethality of taipoxin is due to the very basic alpha subunit. The molecular weights of alpha, beta and gamma subunits of taipoxin are 13,750, 13,473 and 18,354 daltons respectively. [0004]
  • To date numerous growth factors have been isolated from various sources, and have been characterized To name a few, epidermal growth factor (EGF), fibroblast growth factor (FGF), nerve growth factor OGF) and platelet derived growth factor (PDGF). [0005]
  • It is an object of this invention that the beta taipoxin as a cell growth factor can be used to grow cells in serum free medium. Routinely, cells are grown in the presence of 5 to 20% fetal bovine serum (FBS) for research or production. The purification of products derived from cells grown in serum containing medium is a cumbersome task and furthermore, fetal bovine serum is the most expensive ingredient of the medium A mitogen like cell growth factor will provide serum free environment with adequate cell proliferation. [0006]
  • A further object of this invention is to provide non-toxic beta taipoxin having mitogenic activity as a composition for the promotion of rapid burn and wound healing. In the case of cuts, surgical incisions, and abrasions to lessen the risk of infection and to shorten recovery time. [0007]
  • SUMMARY OF THE INVENTION
  • Cell growth factor has been isolated as the beta subunit of taipoxin by fractionating [0008] Oxyuranus s. scutellatus snake venom by high pressure liquid chromatography. After testing for mitogenic activity in all fractions, the mitogenic activity was revealed in one of the fractions. Cell growth factor is a beta taipoxin; which is a non-toxic fraction of snake venom and is a potent mitogen. Cell growth factor has been isolated from the venom of the poisonous snake species Oxyuranus s. scutellatus.
  • The concentration of 0.1 μg/ml of the beta taipoxin non-toxic subunit becomes a cell growth factor and in serum free medium it gives growth equivalent to medium containing 10% serum for a wide range of cells. Cell growth factor is a beta taipoxin peptide having a molecular weight 14,000 daltons. In vivo experiments proved that beta taipoxin as a cell growth factor acts as a potent mitogen. The cut portion of mouse hip skin healed much faster when cell growth factor was applied as compared to the control counter part. Cell growth factor helped heal a chronic foot wound of a friend. Cell growth factor is claimed as wound healer and its use may be extended to treat burns. [0009]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a high pressure liquid chromatography profile of [0010] Oxyuranus s. scutellatus venom, resolved into 11 major fractions. Peak number 6 is representative of beta taipoxin.
  • FIG. 2 is a high pressure liquid chromatography profile of concentrated [0011] fraction number 6 containing beta taipoxin.
  • FIG. 3 is an electrophoresis profile of beta taipoxin on a 14% Novex gel, showing the molecular weight in the vicinity of 14,000 daltons, when compared with Novex protein markers lysozyme, and trypsin inhibitor, having molecular weights 14,400 and 21,500 daltons respectively on 14 % precast gel. [0012] Lanes 1 and 2 contain the cell growth factor, lane 3 contains the markers.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The cell growth factor consists essentially of a peptide of which first 15 amino acid sequence is: Asp-Leu-Val-Glu-Phe-Gly-Lys-Met-Ile-Glu-Cys-Ala-Ile-Arg-Asn, which is exactly similar to beta taipoxin. For convenience this sequence is referred herein as SEQ ID No: 1. It is believed that any peptide having the partial amino acid sequence SEQ ID No: 1 exhibits substantial utility as a cell growth promoter, a potent mitogen, regardless whether it is synthesized or derived from natural sources. By the term, cell growth factor, we mean a substance whose presence produces a substantial nmitogenic effect on various types of cells, and that the mitogenic effect is indicated, by an increase in cell growth or by a decreased duplication time of various types of cells. [0013]
  • Preferably, the peptide cell growth factor contains the first fifteen amino acids at N-terminal as given by SEQ ID No: 1, and has a molecular weight of about 14,000 daltons revealed by electrophoresis which is similar to beta taipoxin. In addition, cell growth factor is water soluble and stable at 4 ° C. storage for its biological activity. Cell growth factor is stable at room temperature, 74 ° C. for several weeks and its biological mitogenic activity is not altered by exposing it to ultra violet light overnight. [0014]
  • Cell growth factor, beta taipoxin, may be obtained essentially as a fraction of venom, from species of poisonous snake. Cell growth factor is preferably obtained from the venom of a species of Australian taipan snake, particularly the species [0015] Oxyuranus s. scutellatus.
  • The non-toxic beta taipoxin which is an active cell growth factor is obtained by separating the peptide fraction by, high pressure liquid chromatography, using ion exchange chromatography. [0016]
  • Fractionation of Venom
  • The active cell growth factor, a non-toxic beta taipoxin is preferably separated from fresh frozen venom, although lyophilized whole venom may also be used. The liquid venom is diluted 1:1 with 0,01 M phosphate buffer saline (PBS) and preferably centrifuged to sediment insoluble debris, which can also be removed by filtration. Typically, the diluted and centrifuged 50 mg venom is loaded on high pressure liquid chromatography, from Toso Co. Japan and the ion exchange column from Polymer Laboratories UK, maintained at 20 ° C. temperature. A plurality of fractions according to the relative ionic charge are eluted preferably, using gradient Tnzma(2-amino-2-(hydroxymethyl)propane-1,3-diol)-HCl buffer pH 7.3. The Toso high pressure liquid chromatography automatically mixes 1.0 molar Triztna-HCL buffer with water to yield gradient Trizma-HCl buffer from 0.01 molar to 1.0 molar. Any suitable gradient buffer may be used and Trizma-HCl buffer having pH 6.0 to 8.0 can be used. [0017]
  • The venom of [0018] Oxyuranus s. scutellatus resolved into 11 major fractions by high pressure liquid chromatography (Drawing No. 1). Fraction 6 represents the active cell growth factor of beta taipoxin. The fraction containing the mitogenic active peptide may be used in this form as a cell growth promoter, but may also be and preferably is further purified to obtain 100% purity to substantially remove mitogenic inactive substances as well. Preferably, the mitogenic active fraction 6 is concentrated and dialyzed simultaneously using dialysis apparatus from Spectrum Co., to 1/20 volume and further purified by high pressure liquid chromatography as second run under identical conditions, such as gradient buffer temperature etc. The second time running of the concentrate of the cell growth factor fraction 6 resolved into one peak (Drawing No. 2). This peak material is sequenced for its first fifteen amino acids from the N-terminal SEQ ID No:
  • 1 and was found to be exactly similar to beta taipoxin. [0019]
  • Initially each fraction was tested for the cell proliferative activity on rat adrenal pheochromocytoma, PC12, cells in concentrations ranging from 5 μg/ml to 0.1 μg/ml. PC12 cells were maintained in Dulbecco Modified Eagle's Medium (DMEM) serum free medium and various concentrations of 11 fractions were added. The growth pattern of PC12 cells in presence of each fraction was compared to the cells maintained in DMEM containing 10% serum. All fractions showed toxic effect when the concentration of the fraction was greater than 1 μg/ml. However, [0020] fraction 6 of Oxyuranus S. scutellatus venom showed proliferative growth of PC12 cells at 1, 0.5 and 0.1 μg/ml concentration.
  • The proliferative of cell growth factor was studied on wide range of cells of primary and secondary cultures. The results on primary cell cultures are shown in table 1. [0021]
    TABLE 1
    Growth stimulating effect of cell growth factor on primary cultures
    of mouse kidney and spleen cells versus conventional medium
    containing 10% FBS and serum free medium
    Mouse Kidney Mouse Spleen
    Medium 48 hours 96 hours 48 hours 96 hours
    10% FBS ++ ++++ ++
    no FBS +
    no FBS + 0.5 μg/ml +++ ++++ ++ ++
    CGF
    no FBS + ++ ++++ ++ ++
    0.1 μg/ml CGF
  • [0022]
    TABLE 2
    Growth stimulating effect of cell growth factor on PC12 Cells*
    Incubation period
    Medium 48 hours 96 hours
    10% FBS 2.3 × 105 4.3 × 105
    Serum free 1.0 × 105 0.6 × 105
    serum free + toxic toxic
    5 μg/ml CGF
    serum free + 1.9 × 105 2.1 × 105
    1 μg/ml CGF
    serum free + 2.3 × 105 4.0 × 105
    0.5 μg/ml CGF
    serum free + 2.4 × 105 4.3 × 105
    0.1 μg/ml CGF
  • [0023]
    TABLE 3
    Growth stimulating effect of cell growth factor on various
    established cell lines
    Serum free medium
    Cell Line none 0.1 μg/ml 0.5 μg/ml 10% FBS
    Chang's liver retarded normal normal normal
    NIH 3T3 retarded normal normal normal
    Skin no growth normal normal normal
    NS-20 retarded normal normal normal
    PC-12 retarded neurite neurite normal
    SP/2 no growth no growth no growth normal
  • The results show that cell growth factor is nitogenic for most of the cells tested. Cell growth factor seems to be neurotrophic as PC12 cells show neurite outgrowth in the presence of this growth factor. [0024]
  • Experimental cuts were made on both hips of test mnice. The right cuts were treated with cell growth factor and the left with PBS. The cuts treated with cell growth factor healed much faster. [0025]
  • A friend, experienced a deep wound on the top of his foot, which showed non closure after 3 months and was deemed to be chronic. After applying cell growth factor, twice a day, his wound began to heal. He experienced the effect of cell growth factor within 24 hours. [0026]
  • Therefore, cell growth factor can be a wound healer. [0027]
  • Cell growth factor is stable at 4° C. for a long period of time. Cell growth factor is non-toxic, when 50 μg in 0.5 ml is injected intraperitoneally in a 20 gram mouse. Being a cell growth promoter having a neurotrophic activity, this cell growth factor will be an excellent wound and burn healer. [0028]
  • The cell growth factor is beta taipoxin of the present invention is a particularly effective mitogenic agent. Since it is substantially free of toxic activity, the cell growth factor can be used to grow wide range of cells in the serum free medium. Further, it may be used for a rapid proliferation of cells either for research or for production purposes, also in the case of dermal monolayers to grow in vitro for the treatment of bum victims and for wound healing. [0029]
  • It is further believed that cell growth factor, which is a beta taipoxin, and its method of preparation of the present invention has utility for treating bums and wounds including chronic wounds. Generally, the healing effects is accomplished by treating the wounds or cuts with cell growth factor having 100 μg/ml protein concentration in PBS in liquid form. It can be used after mixing with silvadene or any other appropriate ointment. The application of cell growth factor once or twice a day on the afflicted area, followed by dressing with silvadeen, the healing effect starts within 24 hours. Moreover, after the wound is healed, no scar is produced because the hard dead tissue on the wound sloughs off as a effect of cell growth factor. [0030]
  • Analysis of the Cell Growth Gactor Active Peptide
  • The [0031] concentrated fraction number 6 which was obtained by initial fractionating the crude venom, resolved into a single peak on second time fractionation on high pressure liquid chromatography under identical conditions. The peak material was estimated to have a molecular weight in the vicinity of 14,000 daltons, when compared with Novex protein markers lysozyme, and trypsin inhibitor, having molecular weights 14,400 and 21,500 daltons respectively on 14% precast gel (Drawing No. 3).
  • The forgoing description of the invention is illustrative and explanatory thereof, and many variations will occur to those in the art. It is intended that all such variations within the scope and spirit of the appended claims be embraced thereby. [0032]
  • 1 1 1 15 PRT OXYURANUS SCUTELLATUS ISOLATE FROM VENOM 1 Asp Leu Val Glu Phe Gly Lys Met Ile Glu Cys Ala Ile Arg Asn 5 10 15

Claims (7)

What is claimed is:
1. A culture medium characterized by the presence of a peptide containing a sequence for the first fifteen amino acids from the N-terminal of Asn-Leu-Val-Glu-Phe-Gly-Lys-Met-Ile-Glu-Cys-Ala-Ile-Arg-Asn identified in SEQ ID No: 1.
2. A culture medium as in claim 1 further characterized in that the peptide comprises beta taipoxin obtained from snake venom.
3. A culture medium as in claim 2 further characterized in that the beta taipoxin is obtained from the species Oxyuranus s. scutellatus, an Australian taipan snake.
4. A culture medium as in claim 3, further characterized by the absence of serum.
5. A culture medium as in claim 4 further characterized in that the beta taipoxin has a molecular weight of about 14,000 daltons and is present at a concentration in the range of from about 0.1 μg/ml to about 1 μg/ml.
6. A method for cultivating various types of eukaryotic cells, said method comprising providing a cell culture medium;
placing cells in the cell culture medium; and
cultivating said cells,
characterized in that the cell culture medium contains a peptide containing a sequence for the first fifteen amino acids from the N-terminal of Asn-Leu-Val-Glu-Phe-Gly-Lys-Met-Ile-Glu-Cys-Ala-Ile-Arg-Asn identified in SEQ ID No: 1.
7. A method as in claim 6 is further characterized in that the cell culture medium is serum free and the peptide comprises beta taipoxin at a concentration in the range of 0.1 μg/ml to 1 μg/ml.
US10/004,085 1994-05-03 2001-10-23 Beta taipoxin as a cell growth factor and method Abandoned US20020106791A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/004,085 US20020106791A1 (en) 1994-05-03 2001-10-23 Beta taipoxin as a cell growth factor and method

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/237,129 US6316602B1 (en) 1994-05-03 1994-05-03 Beta taipoxin as a cell growth factor and method
US08/657,164 US6307031B1 (en) 1994-05-03 1996-06-03 Beta taipoxin as a cell growth factor and method
US10/004,085 US20020106791A1 (en) 1994-05-03 2001-10-23 Beta taipoxin as a cell growth factor and method

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US08/237,129 Division US6316602B1 (en) 1994-05-03 1994-05-03 Beta taipoxin as a cell growth factor and method
US08/657,164 Division US6307031B1 (en) 1994-05-03 1996-06-03 Beta taipoxin as a cell growth factor and method

Publications (1)

Publication Number Publication Date
US20020106791A1 true US20020106791A1 (en) 2002-08-08

Family

ID=22892454

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/237,129 Expired - Fee Related US6316602B1 (en) 1994-05-03 1994-05-03 Beta taipoxin as a cell growth factor and method
US08/657,164 Expired - Fee Related US6307031B1 (en) 1994-05-03 1996-06-03 Beta taipoxin as a cell growth factor and method
US10/004,085 Abandoned US20020106791A1 (en) 1994-05-03 2001-10-23 Beta taipoxin as a cell growth factor and method

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US08/237,129 Expired - Fee Related US6316602B1 (en) 1994-05-03 1994-05-03 Beta taipoxin as a cell growth factor and method
US08/657,164 Expired - Fee Related US6307031B1 (en) 1994-05-03 1996-06-03 Beta taipoxin as a cell growth factor and method

Country Status (6)

Country Link
US (3) US6316602B1 (en)
EP (1) EP0759069B1 (en)
AU (1) AU691621B2 (en)
CA (1) CA2189357A1 (en)
DE (1) DE69525450T2 (en)
WO (1) WO1995029987A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061044A2 (en) * 2001-01-30 2002-08-08 Lipps Binie V Synthetic peptide and uses for same
WO2003072543A2 (en) * 2002-02-21 2003-09-04 Quark Biotech, Inc. Methods of preventing or treating brain ischemia or brain injury
US20060034823A1 (en) * 2004-08-13 2006-02-16 Paul Reid Method of production and use of crotoxin as an analgesic

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443546A (en) * 1980-07-07 1984-04-17 The Beth Israel Hospital Association Process and composition for propagating mammalian cells
US4341762A (en) * 1981-04-07 1982-07-27 Haast William E Use of snake venoms for treatment of neurological and related disorders
US4741902A (en) * 1986-07-14 1988-05-03 Haast William E Compositions for treatment of neurological and related disorders

Also Published As

Publication number Publication date
WO1995029987A1 (en) 1995-11-09
AU2636095A (en) 1995-11-29
DE69525450D1 (en) 2002-03-21
CA2189357A1 (en) 1995-11-09
EP0759069A4 (en) 1998-06-10
EP0759069A1 (en) 1997-02-26
US6307031B1 (en) 2001-10-23
US6316602B1 (en) 2001-11-13
AU691621B2 (en) 1998-05-21
EP0759069B1 (en) 2002-02-13
DE69525450T2 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
Thomas et al. Fibroblast growth factors: broad spectrum mitogens with potent angiogenic activity
Postlethwaite et al. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta.
Erlanson et al. Purification and characterization of two proteins with co-lipase activity from porcine pancreas
CA1300010C (en) Hepatocyte growth factor
Seyedin et al. Purification and characterization of two cartilage-inducing factors from bovine demineralized bone.
EP0419534B1 (en) Wound healing
Nissley et al. Multiplication-stimulating activity (MSA): A somatomedin-like polypeptide from cultured rat liver cells
JPS6136223A (en) Polypeptide cartilage inductive factor in bone
HOFMANN et al. The seminal vesicle of the bull: a new and very rich source of nerve growth factor
GB2146335A (en) Wound healing compositions
Abe et al. Purification of rabbit tumor necrosis factor
US5104977A (en) Purified transforming growth factor beta
Adlakha et al. Partial purification and characterization of mitotic factors from HeLa cells
Asashima et al. The vegetalizing factor from chicken embryos: its EDF (activin A)-like activity
US5070188A (en) Acylated epidermal growth factor
Tokuyama et al. Bovine colostric transforming growth factor-β-like peptide that induces growth inhibition and changes in morphology of human osteogenic sarcoma cells (MG-63)
US20020106791A1 (en) Beta taipoxin as a cell growth factor and method
Tokuyama et al. Purification and identification of TGF-β2-related growth factor from bovine colostrum
RU2136695C1 (en) Serum glycoprotein showing biological activity at superlow doses
Cai et al. Purification and characterization of an endothelial cell-viability maintaining factor from fetal bovine serum
KR920002163B1 (en) Psoriasis treatment with tgf-beta
EP0655251B1 (en) Pharmaceutical composition for preventing or treating bone fractures
Li et al. Mechanical and humoral factors in wound healing
US5545720A (en) Protein PHBP-70
Agrez et al. A fibroblast elongation factor purified from colon carcinoma cells shares sequence identity with TIMP-1

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION